Research Paper Volume 15, Issue 20 pp 11131—11151

Figure 4. Triptolide overcomes SMO mutant-induced drug resistance. (A–C) The BODIPY-cyclopamine (5 nM) competitive binding assay was separately examined by fluorescent microscope and flow cytometry, Cyclopamine (5 μM) was used as a positive control. (C) Quantification of flow cytometry following BODIPY-cyclopamine competitive binding assay analysis was exhibited. Scale bar: 100 μm. (D, E) Western blot was used to detect the effect of TPL on the expression of Gli1 and ptch1 in NIH3T3 cells after overexpression of SMO473H, and GDC0449 (1 μM) was used to control. All results were derived from three independent repeated experiments and represented by mean ± SD, * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. vector; # p < 0.05, ## p < 0.01 and ### p < 0.001 vs. BODIPY-cyclopamine or SMO473H group; ns, no significance.